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Background

Results (cont.)

Gating Strategy

• Knowledge about the nature of T cells in cancer, particularly memory T cells, is vital

prior to potential incorporation into immunotherapies for leukemia such as:
• Immune checkpoint inhibitors
Bone Marrow

• Bispecific T-cell engagers
• Chimeric antigen receptor (CAR) tumor-specific T cells
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• Tscm, the most recently characterized of these is of interest due to its:
• Longevity
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• The live cell percent was lower at diagnosis than D29 (PB- 57.2% vs 79.4%, p=0.001;
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BM- 41.7% vs 77.0%, p<0.001).
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• The absolute cell counts were not significantly different between diagnosis and D29.
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Results

• Objective: To determine potential presence and frequency of memory T cell

populations in human leukemia at diagnosis and after induction chemotherapy.
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• Ability to create the full spectrum of memory CD8+ T cells
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• Self-renewal properties
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are further classified into central memory T cells (Tcm), effector memory T cells
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• T cells are made up of diverse subpopulations including memory CD8+ T cells which
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* Each color represents an individual
patient. Most patients (though not
all) had a diagnostic and D29 sample
from both BM and PB

Conclusions

• T cell frequencies were lower at D29 (PB- 14.8% vs 5.74%, p=0.014; BM- 9.5% vs 5.9%,
p=0.217).
• CD4+ T cells and CD8+ T cells were not significantly different between diagnosis and
D29.

Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health
and disease. Nat Med. 2017;23(1):18-27. doi:10.1038/nm.4241

• Among CD8+ T cells, naïve cells markedly increased from diagnosis to D29 (PB- 53.6%
vs 82.2%, p<0.001; BM- 38.8% vs 80.3%, p<0.001) with a corresponding significant

Methods
• Children’s Mercy Cancer Center Biorepository provided samples from 16 patients
with premature B cell acute lymphoblastic leukemia (pre-B ALL) from peripheral
blood (PB) and/or bone marrow (BM).

• Timepoints were at diagnosis and day 29 (D29) of induction chemotherapy.
• Flow cytometric analysis of cytotoxic memory T cell populations was performed and
analyzed using descriptive statistics and the t-test.

decrease in Tem (PB- 15.1% vs 4.2%, p=0.002; BM- 21.6% vs 4.7%, p<0.001).
• Tscm (reported as a percentage of CD8+ T cells) were detected in all samples at
diagnosis (PB range- 0.49-12.2%; BM range- 0.12-4.4%).

• After induction chemotherapy, two patients had no Tscm detected. The remainder
demonstrated varying numbers of Tscm (PB range- 0.038-23.4%; BM range- 0.01317.4%).
• Differences between diagnosis and D29 were not significant; however, percentages of
Tscm were lower in 9 of 12 patients after chemotherapy.

• Induction chemotherapy led to decreased differentiated CD8 + T cells with
recovery of mostly naïve cells by D29.

• Furthermore, we established the presence of Tscm in most pediatric pre-B ALL
samples.
• The decline of Tscm in most patients requires functional analyses to determine
their role in leukemia and potential for use in immunotherapy.
• Studies are ongoing to detect differences in memory T cell populations based on

response to induction chemotherapy.
• Further study is needed to investigate the potential impact of these changes on
risk of relapse.
• References available upon request
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